185 related articles for article (PubMed ID: 11532627)
1. Chitotriosidase genotype and plasma activity in patients type 1 Gaucher's disease and their relatives (carriers and non carriers).
Giraldo P; Cenarro A; Alfonso P; Pérez-Calvo JI; Rubio-Félix D; Giralt M; Pocoví M
Haematologica; 2001 Sep; 86(9):977-84. PubMed ID: 11532627
[TBL] [Abstract][Full Text] [Related]
2. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring.
Irún P; Alfonso P; Aznarez S; Giraldo P; Pocovi M
Clin Biochem; 2013 Dec; 46(18):1804-7. PubMed ID: 24060732
[TBL] [Abstract][Full Text] [Related]
3. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring.
Grace ME; Balwani M; Nazarenko I; Prakash-Cheng A; Desnick RJ
Hum Mutat; 2007 Sep; 28(9):866-73. PubMed ID: 17464953
[TBL] [Abstract][Full Text] [Related]
4. [Comparison and clinical application of two methods for determination of plasma chitotriosidase activity].
Wang Y; Zhang HW; Ye J; Qiu WJ; Han LS; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):834-8. PubMed ID: 23302614
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of Gaucher patients with a novel chitotriosidase assay.
Schoonhoven A; Rudensky B; Elstein D; Zimran A; Hollak CE; Groener JE; Aerts JM
Clin Chim Acta; 2007 Jun; 381(2):136-9. PubMed ID: 17408605
[TBL] [Abstract][Full Text] [Related]
6. [Plasma chitotriosidase activity in Argentinian patients with Gaucher disease, various lysosomal diseases and other inherited metabolic disorders].
Dodelson de Kremer R; Paschini de Capra A; Angaroni CJ; Giner de Ayala A
Medicina (B Aires); 1997; 57(6):677-84. PubMed ID: 9674188
[TBL] [Abstract][Full Text] [Related]
7. Co-morbidity in Gaucher's disease results of a nationwide enquiry in Spain.
Pérez-Calvo J; Bernal M; Giraldo P; Torralba MA; Civeira F; Giralt M; Pocovi M
Eur J Med Res; 2000 Jun; 5(6):231-5. PubMed ID: 10882637
[TBL] [Abstract][Full Text] [Related]
8. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characterization of chitotriosidase enzyme: comparison between normal individuals and patients with Gaucher and with Niemann-Pick diseases.
Wajner A; Michelin K; Burin MG; Pires RF; Pereira ML; Giugliani R; Coelho JC
Clin Biochem; 2004 Oct; 37(10):893-7. PubMed ID: 15369720
[TBL] [Abstract][Full Text] [Related]
10. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease.
Wajner A; Michelin K; Burin MG; Pires RF; Pereira ML; Giugliani R; Coelho JC
Clin Biochem; 2007 Mar; 40(5-6):365-9. PubMed ID: 17291472
[TBL] [Abstract][Full Text] [Related]
12. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak CE; van Weely S; van Oers MH; Aerts JM
J Clin Invest; 1994 Mar; 93(3):1288-92. PubMed ID: 8132768
[TBL] [Abstract][Full Text] [Related]
13. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
14. Blood oxidative stress markers in Gaucher disease patients.
Roversi FM; Galdieri LC; Grego BH; Souza FG; Micheletti C; Martins AM; D'Almeida V
Clin Chim Acta; 2006 Feb; 364(1-2):316-20. PubMed ID: 16125160
[TBL] [Abstract][Full Text] [Related]
15. Allelic frequency determination of the 24-bp chitotriosidase duplication in the Portuguese population by real-time PCR.
Rodrigues MR; Sá Miranda MC; Amaral O
Blood Cells Mol Dis; 2004; 33(3):362-4. PubMed ID: 15528158
[TBL] [Abstract][Full Text] [Related]
16. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics of type I Gaucher's disease in Spain. Preliminary results of national survey. Spanish Group on Gaucher's Disease].
Giraldo P; Pérez-Calvo JI; Giralt M; Pocovi M
Med Clin (Barc); 1997 Nov; 109(16):619-22. PubMed ID: 9463135
[TBL] [Abstract][Full Text] [Related]
18. Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations.
Alfonso P; Cenarro A; Pérez-Calvo JI; Giralt M; Giraldo P; Pocoví M
Blood Cells Mol Dis; 2001; 27(5):882-91. PubMed ID: 11783951
[TBL] [Abstract][Full Text] [Related]
19. [Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease].
Alfonso P; Cenarro A; Pérez-Calvo JI; Puzo J; Giralt M; Giraldo P; Pocoví M
Med Clin (Barc); 2003 May; 120(17):641-6. PubMed ID: 12747811
[TBL] [Abstract][Full Text] [Related]
20. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
